We are live on ! Find out more
BLUE

bluebird bio
BLUE

Delisted

BLUE was delisted on the 30th of May, 2025.

Back to rankings

288 hedge funds and large institutions have $9.81B invested in bluebird bio in 2019 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 106 increasing their positions, 79 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 28

62% more capital invested

Capital invested by funds: $6.04B → $9.81B (+$3.77B)

62% more call options, than puts

Call options by funds: $141M | Put options by funds: $87.5M

34% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 79

15% more funds holding

Funds holding: 251 → 288 (+37)

0.13% more ownership

Funds ownership: 8.63% → 8.76% (+0.13%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
288
Holders Change
+37
Holders Change %
+14.74%
% of All Funds
6.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
65
Increased
106
Reduced
79
Closed
28
Calls
$141M
Puts
$87.5M
Net Calls
+$53.9M
Net Calls Change
-$26.9M

Top Buyers

Rank Fund Capital Flow
1
MWNA
Marshall Wace North America
New York
+$64.7M
2
Bank of America
Bank of America
North Carolina
+$50.4M
3
Capital World Investors
Capital World Investors
California
+$42.4M
4
HM
HealthCor Management
New York
+$41.2M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$35.8M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$38.4M
2
Two Sigma Investments
Two Sigma Investments
New York
-$25.3M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$21M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$10.9M
5
AG
Artal Group
Luxembourg
-$10.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Eventide Asset Management
Massachusetts
$46.4M +$2.32M +1,315 +6%
Jennison Associates
27
Jennison Associates
New York
$44.5M -$72.2K -41 -0.2%
EAM
28
Eagle Asset Management
Florida
$44.4M +$477K +271 +1%
Deutsche Bank
29
Deutsche Bank
Germany
$43.3M +$1.04M +589 +3%
Northern Trust
30
Northern Trust
Illinois
$41.7M +$912K +518 +3%
Charles Schwab
31
Charles Schwab
California
$36.8M +$2.34M +1,329 +8%
CTA
32
Carillon Tower Advisers
Florida
$35.2M – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$33.7M -$1.49M -849 -5%
Ameriprise
34
Ameriprise
Minnesota
$33.3M +$7.78M +4,418 +37%
Morgan Stanley
35
Morgan Stanley
New York
$33.1M -$4.71M -2,674 -14%
TA
36
Teachers Advisors
New York
$32M -$3.24M -1,839 -10%
TCIM
37
TIAA CREF Investment Management
New York
$29.3M -$5.82M -3,303 -19%
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$26.6M -$81K -46 -0.4%
CS
39
Candriam SCA
Luxembourg
$26.6M – – –
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$26.4M +$1.18M +672 +5%
AIM
41
ARK Investment Management
Florida
$24.5M -$5.63M -3,199 -21%
Mitsubishi UFJ Trust & Banking
42
Mitsubishi UFJ Trust & Banking
Japan
$23.6M -$93.3K -53 -0.5%
Franklin Resources
43
Franklin Resources
California
$23.4M – – –
FCM
44
Frontier Capital Management
Massachusetts
$23.2M -$291K -165 -1%
MMH
45
Menora Mivtachim Holdings
Israel
$22.3M – – –
Millennium Management
46
Millennium Management
New York
$21.5M +$243K +138 +1%
Wells Fargo
47
Wells Fargo
California
$20.5M +$5.01M +2,843 +39%
Invesco
48
Invesco
Georgia
$16.6M +$699K +397 +5%
PAMU
49
Pictet Asset Management (UK)
United Kingdom
$16.3M +$130K +74 +0.9%
AG
50
Artal Group
Luxembourg
$15.7M -$10.2M -5,790 -43%
1
2
3 4 5

BLUE Hedge Fund Activity: Q1 2019 in Review

288 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q1 2019, worth a combined $9.81B — up 62% from $6.04B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new BLUE positions and 28 closed out — a net gain of 37 holders — while 106 added to existing stakes and 79 trimmed.

The largest buyer was Marshall Wace North America, opening a new position worth an estimated $64.7M. The largest seller was OrbiMed, exiting entirely with an estimated $38.4M sold.

  • 288 institutional investors held bluebird bio (BLUE) as of Q1 2019, up from 251 in Q4 2018.
  • Funds reported $9.81B of bluebird bio stock for Q1 2019, up 62% quarter-over-quarter.
  • 65 funds opened new bluebird bio positions in Q1 2019 and 28 closed out, a net change of +37 holders.
  • The largest bluebird bio buyer in Q1 2019 was Marshall Wace North America, an estimated $64.7M added.
  • The largest bluebird bio seller in Q1 2019 was OrbiMed, an estimated $38.4M sold.

Based on aggregated 13F filings for Q1 2019.